{"groups":[{"description":"Once eligibility is confirmed, the patient will start treatment cycles with Pembrolizumab at 200 mg given intravenously on the first day of each cycle. Each cycle corresponds to a duration of 3 weeks.\n\nPembrolizumab: Pembrolizumab will be administered intravenously every 3 weeks.","id":"FG000","title":"Pembrolizumab 200 mg"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"6"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"6"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}